Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report

IF 1.9 4区医学 Q2 OTORHINOLARYNGOLOGY

European Annals of Otorhinolaryngology-Head and Neck Diseases Pub Date : 2024-08-01 DOI:10.1016/j.anorl.2024.02.003

{"title":"Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report","authors":"","doi":"10.1016/j.anorl.2024.02.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Analysis of rechallenge with nivolumab<span> as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma<span> following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.</span></span></p></div><div><h3>Observation</h3><p><span><span>A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with </span>chemoradiotherapy<span> and surgery, was initially treated for recurrence with carboplatin<span>, 5-fluorouracile (FU) and cetuximab<span><span>, followed by second-line nivolumab<span>, and then two lines of conventional chemotherapy with paclitaxel and </span></span>cetuximab<span> followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12</span></span></span></span></span>  <!-->months’ survival since initiation of exclusive systemic management after failure of conventional treatment.</p></div><div><h3>Conclusion</h3><p>This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.</p></div>","PeriodicalId":48834,"journal":{"name":"European Annals of Otorhinolaryngology-Head and Neck Diseases","volume":"141 4","pages":"Pages 231-234"},"PeriodicalIF":1.9000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Annals of Otorhinolaryngology-Head and Neck Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879729624000206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Analysis of rechallenge with nivolumab as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.

Observation

A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with chemoradiotherapy and surgery, was initially treated for recurrence with carboplatin, 5-fluorouracile (FU) and cetuximab, followed by second-line nivolumab, and then two lines of conventional chemotherapy with paclitaxel and cetuximab followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12 months’ response, ongoing at the time of writing, and 42.5 months’ survival since initiation of exclusive systemic management after failure of conventional treatment.

Conclusion

This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.

查看原文本刊更多论文

常规治疗失败后，Nivolumab 免疫疗法再挑战治疗进展期喉鳞癌：CARE病例报告

在采用放疗、手术和化疗等常规治疗方法后，对局部和结节治疗失败的喉鳞癌进行再挑战nivolumab作为五线疗法的分析。一位70岁的男性患者在接受化放疗和手术治疗后，喉鳞状细胞癌出现局部和结节进展，他最初接受了卡铂、5-氟尿嘧啶（FU）和西妥昔单抗的复发治疗，随后接受了二线尼伐单抗治疗，之后又接受了紫杉醇和西妥昔单抗的两线常规化疗，之后又接受了卡铂和西妥昔单抗治疗。他在第五线接受了 nivolumab 的再挑战，获得了 12 个月的应答，在撰写本报告时仍在进行中，并且自常规治疗失败后开始接受独家系统治疗以来获得了 42.5 个月的生存期。本病例报告强调了在常规治疗后局部和结节未受控制的喉鳞癌患者，在二线独立治疗失败后，在五线接受尼妥珠单抗再挑战治疗的益处。有必要进行临床试验，评估这种方法的疗效，因为它目前还不是标准治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Annals of Otorhinolaryngology-Head and Neck Diseases OTORHINOLARYNGOLOGY-

CiteScore

3.70

自引率

28.00%

发文量

审稿时长

12 days

期刊介绍： European Annals of Oto-rhino-laryngology, Head and Neck diseases heir of one of the oldest otorhinolaryngology journals in Europe is the official organ of the French Society of Otorhinolaryngology (SFORL) and the the International Francophone Society of Otorhinolaryngology (SIFORL). Today six annual issues provide original peer reviewed clinical and research articles, epidemiological studies, new methodological clinical approaches and review articles giving most up-to-date insights in all areas of otology, laryngology rhinology, head and neck surgery. The European Annals also publish the SFORL guidelines and recommendations.The journal is a unique two-armed publication: the European Annals (ANORL) is an English language well referenced online journal (e-only) whereas the Annales Françaises d’ORL (AFORL), mail-order paper and online edition in French language are aimed at the French-speaking community. French language teams must submit their articles in French to the AFORL site. Federating journal in its field, the European Annals has an Editorial board of experts with international reputation that allow to make an important contribution to communication on new research data and clinical practice by publishing high-quality articles.